J&J Oncology Head Confident About Fast-Tracked Daratumumab's Chances
This article was originally published in Scrip
Executive Summary
Johnson & Johnson says it is increasingly confident its anti-CD38 monoclonal antibody daratumumab will get final approval in both the US and Europe after being fast-tracked by regulators in both regions for treating multiple myeloma, an incurable blood cancer.